Skip to main content

Dr. Karl G. Csaky, MD

Ophthalmology (Ophthalmology Physician)

At a glance

In the NPI registry since
2007

Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Ophthalmology Physician primary
    TX license N3584 (first issued 2009; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Ophthalmology per capita by county →

Payments from drug and device companies

In 2025, 11 companies reported 33 payments worth $55,582 in total to this clinician.

By company
F. Hoffmann-la Roche AG$11,059
Boehringer Ingelheim International GmbH$10,560
Genentech, Inc.$9,117
Apellis Pharmaceuticals, Inc.$7,193
Biocryst Pharmaceuticals, Inc.$5,263
Astellas Pharma Europe LTD$3,126
Bausch & Lomb Americas Inc.$3,048
Genentech USA, Inc.$3,017
By type
Consulting Fee$46,732
Travel and Lodging$7,683
Food and Beverage$1,167

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 16, 2025Genentech, Inc.
Jun 16, 2025
Consulting Fee$9,000
Dec 8, 2025F. Hoffmann-la Roche AG
Dec 8, 2025
Consulting Fee$7,497
May 8, 2025Apellis Pharmaceuticals, Inc.
May 8, 2025
Consulting Fee$7,000
Feb 14, 2025Boehringer Ingelheim International GmbH
Feb 14, 2025
Travel and Lodging
travel to Mainz, Germany · in-kind
$6,600
Sep 24, 2025Biocryst Pharmaceuticals, Inc.
Sep 24, 2025
Consulting Fee$5,192
Oct 13, 2025Astellas Pharma Europe LTD
Oct 13, 2025
Consulting Fee
Izervay · Ophthalmology
$3,126
Oct 16, 2025Bausch & Lomb Americas Inc.
Oct 16, 2025
Consulting Fee$3,000
Apr 5, 2025Genentech USA, Inc.
Apr 5, 2025
Consulting Fee
Vabysmo · Immunology and Ophthalmology
$2,995
Feb 14, 2025Boehringer Ingelheim International GmbH
Feb 14, 2025
Consulting Fee$2,640
Jan 22, 2025Boehringer Ingelheim International GmbH
Jan 22, 2025
Consulting Fee$1,320
All 19 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 8, 2025F. Hoffmann-la Roche AG
Dec 8, 2025
Consulting Fee$7,497
Dec 8, 2025F. Hoffmann-la Roche AG
Dec 8, 2025
Travel and Lodging
travel to Basel, Switzerland
$798
Dec 8, 2025F. Hoffmann-la Roche AG
Dec 8, 2025
Travel and Lodging
travel to Basel, Switzerland
$253
Dec 8, 2025F. Hoffmann-la Roche AG
Dec 8, 2025
Travel and Lodging
travel to Basel, Switzerland
$32.56
Nov 4, 2025AbbVie Inc.
Nov 4, 2025
Consulting Fee
OZURDEX · EYE CARE
$850
Oct 24, 2025Regeneron Pharmaceuticals, Inc.
Oct 24, 2025
Consulting Fee
VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY
$940
Oct 24, 2025Regeneron Pharmaceuticals, Inc.
Oct 24, 2025
Consulting Fee
VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY
$470
Oct 16, 2025Bausch & Lomb Americas Inc.
Oct 16, 2025
Consulting Fee$3,000
Oct 13, 2025Astellas Pharma Europe LTD
Oct 13, 2025
Consulting Fee
Izervay · Ophthalmology
$3,126
Sep 24, 2025Biocryst Pharmaceuticals, Inc.
Sep 24, 2025
Consulting Fee$5,192
Jul 9, 2025Regeneron Pharmaceuticals, Inc.
Jul 9, 2025
Consulting Fee
VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY
$602
Jun 16, 2025Genentech, Inc.
Jun 16, 2025
Consulting Fee$9,000
May 8, 2025Apellis Pharmaceuticals, Inc.
May 8, 2025
Consulting Fee$7,000
May 4, 2025F. Hoffmann-la Roche AG
May 4, 2025
Consulting Fee$1,260
Apr 5, 2025Genentech USA, Inc.
Apr 5, 2025
Consulting Fee
Vabysmo · Immunology and Ophthalmology
$2,995
Feb 14, 2025Boehringer Ingelheim International GmbH
Feb 14, 2025
Travel and Lodging
travel to Mainz, Germany · in-kind
$6,600
Feb 14, 2025Boehringer Ingelheim International GmbH
Feb 14, 2025
Consulting Fee$2,640
Jan 22, 2025Boehringer Ingelheim International GmbH
Jan 22, 2025
Consulting Fee$1,320
Jan 1, 2025F. Hoffmann-la Roche AG
Jan 1, 2025
Consulting Fee$840

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $1,239,350 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Ma…
    Novartis Pharmaceuticals Corporation
  • A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Prospective assessment of virtual reality-based perimetry to measure retinal sensitivity in patients with non-neovascular (dry) age-related macular degeneration (amd)
    Regeneron Pharmaceuticals, Inc.
  • A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
    Alexion Pharmaceuticals, Inc.
  • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
    AbbVie Inc. · Recruiting · NCT07160179
  • A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound
    Janssen Research & Development, LLC
  • A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
    Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
  • Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
    AbbVie Inc.
  • IAMD Observational Study
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Ophthalmology clinicians in Dallas

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 13, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1144375122. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.